Collaborations

Company amends collaboration with GlaxoSmithKline

Published in Cancer Weekly, February 8th, 2005

Exelixis, Inc., (EXEL) announced it has amended the terms of its collaboration with GlaxoSmithKline, plc, (GSK).

The collaboration between Exelixis and GlaxoSmithKline (GSK) was established in October 2002 to discover and develop novel therapeutics in the areas of vascular biology, inflammatory disease, and oncology.

Under the terms of the original agreement, a 4-month option period began in October, 2004 for GSK to elect whether or not to expand the collaboration. The amended collaboration does not strictly adhere to either one of the options originally envisioned. The amended collaboration provides accelerated milestone payments to Exelixis and...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2005-02-08)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry